Transce3nd LLC Takes Position in Johnson & Johnson (NYSE:JNJ)

Transce3nd LLC bought a new position in Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,126 shares of the company’s stock, valued at approximately $163,000.

Several other large investors have also recently bought and sold shares of the company. Trajan Wealth LLC raised its position in shares of Johnson & Johnson by 11.1% in the fourth quarter. Trajan Wealth LLC now owns 36,664 shares of the company’s stock worth $5,302,000 after buying an additional 3,672 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its stake in Johnson & Johnson by 9.2% in the 4th quarter. Kayne Anderson Rudnick Investment Management LLC now owns 118,700 shares of the company’s stock worth $17,166,000 after acquiring an additional 9,977 shares during the last quarter. Landing Point Financial Group LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth about $319,000. Mirabella Financial Services LLP purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $955,000. Finally, MetLife Investment Management LLC lifted its position in Johnson & Johnson by 1.8% during the fourth quarter. MetLife Investment Management LLC now owns 637,349 shares of the company’s stock valued at $92,173,000 after purchasing an additional 11,299 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ stock opened at $157.42 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a 50-day moving average of $159.49 and a 200 day moving average of $154.95. The company has a market cap of $379.37 billion, a P/E ratio of 23.67, a PEG ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be given a $1.30 dividend. The ex-dividend date is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.30%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on JNJ. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday. Barclays reduced their target price on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Thursday. Raymond James dropped their price target on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $171.82.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.